123I-Metaiodobenzylguanidine Scintigraphy in Parkinson's Disease and Related Disorders
Identifieur interne : 002532 ( Main/Exploration ); précédent : 002531; suivant : 002533123I-Metaiodobenzylguanidine Scintigraphy in Parkinson's Disease and Related Disorders
Auteurs : Olivier Rascol [France] ; Ludwig Schelosky [Suisse]Source :
- Movement disorders [ 0885-3185 ] ; 2009.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Autonomic dysfunction is common in Lewy body disorders (Parkinson's disease, Dementia with Lewy Bodies, Pure Autonomic Failure, and REM sleep disorder). The loss of post-ganglionic myocardial sympathetic nerve fibers is a prominent feature of autonomic dysfunction in such disorders. 123I-metaiodobenzylguanidine (MIBG) scintigraphy that visualizes catecholaminergic terminals in vivo is a biomarker used to detect cardiac sympathetic degeneration. Abnormal MIBG uptake has been consistently reported in Lewy body disorders. Some studies agree in the notion that increasing bradykinesia is related with an incremental cardiac sympathetic denervation, whereas tremor is not closely linked to cardiac denervation. "Atypical" parkinsonian syndromes, including Multiple System Atrophy, Progressive Supranuclear Palsy, and others, show modest reductions of cardial MIBG uptake. MIBG scintigraphy is moderately sensitive and specific in differentiating Parkinson's disease from such syndromes. Conversely, its sensitivity and specificity might be better in cognitively impaired patients, helping differential diagnosis between Dementia with Lewy Bodies, and Alzheimer disease. Confounding factors (comorbidities, comedications) should be carefully controlled before analyzing MIBG scintigraphy.
Affiliations:
- France, Suisse
- Midi-Pyrénées
- Toulouse
- Université Toulouse III - Paul Sabatier, Université de Toulouse
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000C87
- to stream PascalFrancis, to step Curation: 002032
- to stream PascalFrancis, to step Checkpoint: 001011
- to stream Main, to step Merge: 003108
- to stream Main, to step Curation: 002532
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a"><sup>123</sup>I-Metaiodobenzylguanidine Scintigraphy in Parkinson's Disease and Related Disorders</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM CIC-P302 and UMR-825, Departments of Clinical Pharmacology and Neurosciences, CHU and University UPS of Toulouse</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Schelosky, Ludwig" sort="Schelosky, Ludwig" uniqKey="Schelosky L" first="Ludwig" last="Schelosky">Ludwig Schelosky</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Neurologie und klinische Neurophysiologie, Kantonsspital Münsterlingen</s1><s2>Münsterlingen</s2><s3>CHE</s3><sZ>2 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>Münsterlingen</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">10-0038111</idno><date when="2009">2009</date><idno type="stanalyst">PASCAL 10-0038111 INIST</idno><idno type="RBID">Pascal:10-0038111</idno><idno type="wicri:Area/PascalFrancis/Corpus">000C87</idno><idno type="wicri:Area/PascalFrancis/Curation">002032</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001011</idno><idno type="wicri:Area/Main/Merge">003108</idno><idno type="wicri:Area/Main/Curation">002532</idno><idno type="wicri:Area/Main/Exploration">002532</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a"><sup>123</sup>I-Metaiodobenzylguanidine Scintigraphy in Parkinson's Disease and Related Disorders</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM CIC-P302 and UMR-825, Departments of Clinical Pharmacology and Neurosciences, CHU and University UPS of Toulouse</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Schelosky, Ludwig" sort="Schelosky, Ludwig" uniqKey="Schelosky L" first="Ludwig" last="Schelosky">Ludwig Schelosky</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Neurologie und klinische Neurophysiologie, Kantonsspital Münsterlingen</s1><s2>Münsterlingen</s2><s3>CHE</s3><sZ>2 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>Münsterlingen</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2009">2009</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Autonomic nervous system</term><term>Differential diagnostic</term><term>Innervation</term><term>Nervous system diseases</term><term>Parkinson disease</term><term>Scintigraphy</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Scintigraphie</term><term>Système nerveux autonome</term><term>Innervation</term><term>Diagnostic différentiel</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Autonomic dysfunction is common in Lewy body disorders (Parkinson's disease, Dementia with Lewy Bodies, Pure Autonomic Failure, and REM sleep disorder). The loss of post-ganglionic myocardial sympathetic nerve fibers is a prominent feature of autonomic dysfunction in such disorders. <sup>123</sup>I-metaiodobenzylguanidine (MIBG) scintigraphy that visualizes catecholaminergic terminals in vivo is a biomarker used to detect cardiac sympathetic degeneration. Abnormal MIBG uptake has been consistently reported in Lewy body disorders. Some studies agree in the notion that increasing bradykinesia is related with an incremental cardiac sympathetic denervation, whereas tremor is not closely linked to cardiac denervation. "Atypical" parkinsonian syndromes, including Multiple System Atrophy, Progressive Supranuclear Palsy, and others, show modest reductions of cardial MIBG uptake. MIBG scintigraphy is moderately sensitive and specific in differentiating Parkinson's disease from such syndromes. Conversely, its sensitivity and specificity might be better in cognitively impaired patients, helping differential diagnosis between Dementia with Lewy Bodies, and Alzheimer disease. Confounding factors (comorbidities, comedications) should be carefully controlled before analyzing MIBG scintigraphy.</div></front></TEI><affiliations><list><country><li>France</li><li>Suisse</li></country><region><li>Midi-Pyrénées</li></region><settlement><li>Toulouse</li></settlement><orgName><li>Université Toulouse III - Paul Sabatier</li><li>Université de Toulouse</li></orgName></list><tree><country name="France"><noRegion><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></noRegion></country><country name="Suisse"><noRegion><name sortKey="Schelosky, Ludwig" sort="Schelosky, Ludwig" uniqKey="Schelosky L" first="Ludwig" last="Schelosky">Ludwig Schelosky</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002532 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002532 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:10-0038111
|texte= 123I-Metaiodobenzylguanidine Scintigraphy in Parkinson's Disease and Related Disorders
}}
| This area was generated with Dilib version V0.6.23. |  |